BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32298002)

  • 21. Noninvasive proteomic biomarkers for alcohol-related liver disease.
    Niu L; Thiele M; Geyer PE; Rasmussen DN; Webel HE; Santos A; Gupta R; Meier F; Strauss M; Kjaergaard M; Lindvig K; Jacobsen S; Rasmussen S; Hansen T; Krag A; Mann M
    Nat Med; 2022 Jun; 28(6):1277-1287. PubMed ID: 35654907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review.
    Schiffer L; Barnard L; Baranowski ES; Gilligan LC; Taylor AE; Arlt W; Shackleton CHL; Storbeck KH
    J Steroid Biochem Mol Biol; 2019 Nov; 194():105439. PubMed ID: 31362062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression.
    Segovia-Miranda F; Morales-Navarrete H; Kücken M; Moser V; Seifert S; Repnik U; Rost F; Brosch M; Hendricks A; Hinz S; Röcken C; Lütjohann D; Kalaidzidis Y; Schafmayer C; Brusch L; Hampe J; Zerial M
    Nat Med; 2019 Dec; 25(12):1885-1893. PubMed ID: 31792455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Invasive Detection of Early-Stage Fatty Liver Disease via an On-Skin Impedance Sensor and Attention-Based Deep Learning.
    Wang K; Margolis S; Cho JM; Wang S; Arianpour B; Jabalera A; Yin J; Hong W; Zhang Y; Zhao P; Zhu E; Reddy S; Hsiai TK
    Adv Sci (Weinh); 2024 Jun; ():e2400596. PubMed ID: 38887178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New markers of fibrosis in hepatitis C: A step towards the Holy Grail?
    Dabos KJ
    World J Hepatol; 2024 Feb; 16(2):112-114. PubMed ID: 38495275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decompensation in Patients With Advanced NAFLD: More Questions That Need Answering.
    Giri S; Sundaram S
    Clin Gastroenterol Hepatol; 2022 Sep; 20(9):2154-2155. PubMed ID: 34752963
    [No Abstract]   [Full Text] [Related]  

  • 27. Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism.
    Storbeck KH; Schiffer L; Baranowski ES; Chortis V; Prete A; Barnard L; Gilligan LC; Taylor AE; Idkowiak J; Arlt W; Shackleton CHL
    Endocr Rev; 2019 Dec; 40(6):1605-1625. PubMed ID: 31294783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary Fibrosis Diagnosis and Disease Progression Detected Via Hair Metabolome Analysis.
    Miller HA; Suliman S; Frieboes HB
    Lung; 2024 Jun; ():. PubMed ID: 38861171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.
    Ratziu V; Boursier J;
    J Hepatol; 2024 Feb; 80(2):e51-e52. PubMed ID: 37543307
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply.
    Moolla A; Tomlinson JW
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1205-1206. PubMed ID: 32424931
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD?
    Hagström H
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1204-1205. PubMed ID: 32424917
    [No Abstract]   [Full Text] [Related]  

  • 32. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
    Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
    Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    Fan R; Papatheodoridis G; Sun J; Innes H; Toyoda H; Xie Q; Mo S; Sypsa V; Guha IN; Kumada T; Niu J; Dalekos G; Yasuda S; Barnes E; Lian J; Suri V; Idilman R; Barclay ST; Dou X; Berg T; Hayes PC; Flaherty JF; Zhou Y; Zhang Z; Buti M; Hutchinson SJ; Guo Y; Calleja JL; Lin L; Zhao L; Chen Y; Janssen HLA; Zhu C; Shi L; Tang X; Gaggar A; Wei L; Jia J; Irving WL; Johnson PJ; Lampertico P; Hou J
    J Hepatol; 2020 Dec; 73(6):1368-1378. PubMed ID: 32707225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study.
    Chaim FDM; Pascoal LB; Chaim FHM; Palma BB; Damázio TA; da Costa LBE; Carvalho R; Cazzo E; Gestic MA; Utrini MP; Milanski M; Chaim EA; Leal RF
    Sci Rep; 2020 May; 10(1):8496. PubMed ID: 32444690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study.
    Miller H; Harman D; Aithal GP; Manousou P; Cobbold JF; Parker R; Sheridan D; Newsome PN; Karpe F; Neville M; Arlt W; Sitch AJ; Korbonits M; Biehl M; Alazawi W; Tomlinson JW
    BMJ Open; 2024 Jan; 14(1):e074918. PubMed ID: 38238179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Artificial intelligence applied to omics data in liver diseases: Enhancing clinical predictions.
    Baciu C; Xu C; Alim M; Prayitno K; Bhat M
    Front Artif Intell; 2022; 5():1050439. PubMed ID: 36458100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine.
    Shao M; Lu Y; Xiang H; Wang J; Ji G; Wu T
    Front Pharmacol; 2022; 13():971561. PubMed ID: 36091827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatoprotective effect and metabonomics studies of radix gentianae in rats with acute liver injury.
    Xu S; Kong F; Sun Z; Xi Y; Qi F; Sun J
    Pharm Biol; 2021 Dec; 59(1):1172-1180. PubMed ID: 34465274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients.
    Wernberg CW; Ravnskjaer K; Lauridsen MM; Thiele M
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.
    Perakakis N; Stefanakis K; Mantzoros CS
    Metabolism; 2020 Oct; 111S():154320. PubMed ID: 32712221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.